Adjunctive Oral Tacrolimus following fulguration in Hunner’s lesion bladder pain syndrome/ Interstitial cystitis: A Pilot Study

Introduction and Hypothesis: Hunner’s lesion disease is increasingly recognised as a distinct phenotype of bladder pain syndrome/interstitial cystitis (BPS/IC). Given the immune-mediated pathways implicated in its pathogenesis, we hypothesised that adjunctive oral tacrolimus following fulguration may improve symptoms in patients with Hunner’s lesion BPS/IC. Methods In this single-centre prospective pilot study, twelve patients with cystoscopically confirmed Hunner’s lesions received oral tacrolimus (0.04 mg/kg/day) for 10 weeks following standard fulguration. Symptoms were assessed using the validated Apollo clinical scoring system (ACS) at baseline and at 4, 8, and 12 weeks, and 6 months. Tacrolimus trough levels and biochemical safety parameters were monitored serially. Results The median baseline scores were 16/20 for pain, 8/10 for nocturia, 4/5 for urgency, 4/5 for frequency, 4/5 for psychosocial impact, and 37/50 for the overall ACS. Significant improvements in the median overall ACS and all symptom domains were observed at 4, 8, and 12 weeks compared with baseline (p < 0.001). Improvements in the overall ACS and non-pain domains was sustained at 6 months, whereas pain scores no longer differed significantly from baseline (p = 0.067). All patients demonstrated clinically meaningful reduction in ACS, with excellent clinical response (ACS reduction > 30 points) observed in four patients at 4 weeks, and one patient at 6 months. Tacrolimus was generally well tolerated. Mild dyspepsia was the most common adverse event. One patient developed a urinary tract infection responsive to antibiotics, and no clinically significant biochemical toxicities were observed. Conclusion Adjunctive oral tacrolimus following fulguration demonstrated encouraging preliminary signals of clinical benefit with an acceptable safety profile in Hunner’s lesion BPS/IC. Controlled studies are required to determine its incremental efficacy and long-term safety.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11340148/v1
Primary Topic
Urinary Bladder and Prostate Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Adjunctive Oral Tacrolimus following fulguration in Hunner’s lesion bladder pain syndrome/ Interstitial cystitis: A Pilot Study

Kanishak Mehta, Rajesh Taneja, Sanjiv Jasuja, Apeksha Raheja et al.
Research Square
Urinary Bladder and Prostate Research
preprint

Adjunctive Oral Tacrolimus following fulguration in Hunner’s lesion bladder pain syndrome/ Interstitial cystitis: A Pilot Study

Kanishak Mehta, Rajesh Taneja, Sanjiv Jasuja, Apeksha Raheja, Ankur Sharma, Onkar Vats
preprint en

Abstract

Introduction and Hypothesis: Hunner’s lesion disease is increasingly recognised as a distinct phenotype of bladder pain syndrome/interstitial cystitis (BPS/IC). Given the immune-mediated pathways implicated in its pathogenesis, we hypothesised that adjunctive oral tacrolimus following fulguration may improve symptoms in patients with Hunner’s lesion BPS/IC. Methods In this single-centre prospective pilot study, twelve patients with cystoscopically confirmed Hunner’s lesions received oral tacrolimus (0.04 mg/kg/day) for 10 weeks following standard fulguration. Symptoms were assessed using the validated Apollo clinical scoring system (ACS) at baseline and at 4, 8, and 12 weeks, and 6 months. Tacrolimus trough levels and biochemical safety parameters were monitored serially. Results The median baseline scores were 16/20 for pain, 8/10 for nocturia, 4/5 for urgency, 4/5 for frequency, 4/5 for psychosocial impact, and 37/50 for the overall ACS. Significant improvements in the median overall ACS and all symptom domains were observed at 4, 8, and 12 weeks compared with baseline (p < 0.001). Improvements in the overall ACS and non-pain domains was sustained at 6 months, whereas pain scores no longer differed significantly from baseline (p = 0.067). All patients demonstrated clinically meaningful reduction in ACS, with excellent clinical response (ACS reduction > 30 points) observed in four patients at 4 weeks, and one patient at 6 months. Tacrolimus was generally well tolerated. Mild dyspepsia was the most common adverse event. One patient developed a urinary tract infection responsive to antibiotics, and no clinically significant biochemical toxicities were observed. Conclusion Adjunctive oral tacrolimus following fulguration demonstrated encouraging preliminary signals of clinical benefit with an acceptable safety profile in Hunner’s lesion BPS/IC. Controlled studies are required to determine its incremental efficacy and long-term safety.

Research Square
Indraprastha Apollo Hospitals (IN)
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon